Abstract
Genetic factors are known to influence the response of specific medications towards an individual. Appreciating the differences in pharmacokinetics and pharmacodynamics of a drug on an individual helps us understand the drug efficacy and response, which in turn helps with personalized medicine. Genetic polymorphism has been shown to contribute to the effects of several drugs through changes in substrate metabolism and modifications of target/receptor sites.
This chapter reviews the interaction of genetics and cannabis use, specifically how personal genetics can impact an individual’s response to ∆9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). Several enzymes, including CY2C9, AKT1, COMT and CYP2C19 genotypes are clinically relevant markers in determining THC and CBD metabolism status. Through the identification of individual genetic makeup, patients with short- and long-term adverse events such as cannabis-induced psychosis and acute detrimental neurocognitive impairments can be recognized prior to treatment. Through THC and CBD genetic tests, healthcare professionals can optimize specific cannabis strains and appropriate dosing for a patient that provides optimal care and minimizes adverse reactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bland TM, et al. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005;70(7):1096–103.
Sachse-Seeboth C, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. 2009;85(3):273–6.
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.
Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet. 2013;28(1):28–37.
Government of Canada. Information for health care professionals. Cannabis (marihuana, marijuana) and the cannabinoids. 2018. https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf.
National Institute of Drug Abuse. Marijuana. 2018. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/1380-marijuana.pdf.
Nicholson. Spike in cannabis overdoses blamed on potent edibles, poor public education. 2018. https://www.cbc.ca/news/health/cannabis-overdose-legalization-edibles-public-education-1.4800118.
Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371(9):879.
Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction. 2015;110(1):19–35.
Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot—a review of the association between cannabis and psychosis. Front Psych. 2014;5:54.
Morgan CJ, et al. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry. 2016;6(2):e738.
van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011;68(2):148–57.
Di Forti M, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 2012;72(10):811–6.
Cosker E, et al. The effect of interactions between genetics and cannabis use on neurocognition. A review. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:95–106.
Henquet C, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748–57.
Tunbridge EM, et al. Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. J Psychopharmacol. 2015;29(11):1146–51.
Verdejo-GarcÃa A, et al. COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology. 2013;38(8):1598–606.
Schiffman J, et al. Attitudes towards cannabis use and genetic testing for schizophrenia. Early Interv Psychiatry. 2016;10(3):220–6.
National Institute of Drug Abuse. Is there a link between marijuana use and psychiatric disorders? 2020. https://www.drugabuse.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders.
Ujváry I, Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1(1):90–101.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Di Risio, M., Gowd, P. (2022). The Role of Genetics in the Use of Cannabis. In: Valani, R. (eds) Cannabis Use in Medicine. Springer, Cham. https://doi.org/10.1007/978-3-031-12722-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-031-12722-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-12721-2
Online ISBN: 978-3-031-12722-9
eBook Packages: MedicineMedicine (R0)